Company Overview
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and complementary products to detect dangerous and unintended substances in human food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides software systems that help testers analyze and store results; natural toxin tests; rapid sanitation tests; culture and prepared media products; filter tests for microbial analysis of water; sample collection products; and food safety analysis laboratory services. This segment sells its products to the milling and grain, meat and poultry, ready-to-eat, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. Its Animal Safety segment provides reagents and test kits for use in immunoassay production, forensic and animal toxicology, and life science research, as well as colorimetric and chemiluminescent substrates; veterinary instruments and disposables; animal care and other products, including digestive aids and nutritional supplements; rodent and insect control products, and disinfectants; and genomics services, such as DNA genotyping, sequencing, and trait analysis for livestock and companion animals. This segment sells its products to companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Why Investors Should Care
Revenue has grown at a 13.1% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.38.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- May 2025 Revenue of $894.66M (-3.2% YoY); net profit $-1.09B.
- Trailing 12 Months Year-on-year growth — revenue -4.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 13.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 13.13% |
| 1 Year: | -4.40% |
Stock Price Performance
| 1 Year: | +85.25% |
| 6 Months: | +0.52% |
| 3 Months: | +5.80% |
| 1 Month: | +4.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.24 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 13.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NEOG Neogen Corporation R2K | 9.67 | -3.45 | $2.10B | 0.00% | -32.45% | -25.57% | 13.13% | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | May 2015 | Aug 2015 | Nov 2015 | Feb 2016 | May 2016 | Aug 2016 | Nov 2016 | Feb 2017 | May 2017 | Aug 2017 | Nov 2017 | Feb 2018 | May 2018 | Aug 2018 | Nov 2018 | Feb 2019 | May 2019 | Aug 2019 | Nov 2019 | Feb 2020 | May 2020 | Aug 2020 | Nov 2020 | Feb 2021 | May 2021 | Aug 2021 | Nov 2021 | Feb 2022 | Aug 2022 | Nov 2022 | Feb 2023 | Aug 2023 | Nov 2023 | Feb 2024 | Aug 2024 | Nov 2024 | Feb 2025 | Aug 2025 | Nov 2025 | Feb 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 94.21M | 100.70M | 94.90M | - | 99.63M | 107.10M | 97.70M | - | 101.42M | 107.80M | 99.87M | - | 109.33M | 115.00M | 116.71M | - | 128.31M | 130.52M | 128.24M | 132.35M | 230.03M | 218.25M | 228.99M | 229.63M | 228.81M | 216.96M | 231.26M | 221.00M | 209.19M | 224.69M | 211.20M |
| Gross Profit | 37.70M | 37.79M | 38.22M | 35.20M | 41.85M | 40.48M | 43.59M | 40.88M | 47.02M | 44.92M | 48.25M | 44.60M | 48.50M | 46.73M | 50.03M | 44.63M | 50.53M | 48.19M | 51.03M | 45.33M | 51.73M | 50.30M | 53.21M | 53.85M | 57.69M | 60.01M | 60.59M | 57.41M | 62.27M | 112.54M | 107.96M | 116.76M | 116.77M | 116.88M | 104.93M | 113.33M | 110.30M | 94.97M | 106.68M | 99.00M |
| Operating Income | - | 14.89M | 14.61M | 11.25M | - | 14.74M | 16.85M | 14.35M | - | 16.42M | 18.00M | 15.91M | - | 16.48M | 18.25M | 14.64M | - | 16.26M | 18.27M | 13.04M | - | 18.89M | 19.25M | 15.77M | - | 21.75M | 12.47M | 6.38M | 6.06M | -7.66M | 15.68M | 19.14M | 14.46M | 12.02M | 2.26M | -457.48M | 5.40M | -16.09M | -5.38M | -3.30M |
| Net Income | 9.43M | 9.29M | 9.14M | 8.29M | 9.82M | 9.88M | 11.15M | 10.29M | 12.47M | 11.91M | 17.10M | 16.59M | 17.55M | 15.24M | 16.05M | 13.07M | - | 14.65M | 16.28M | 12.20M | - | 15.86M | 15.88M | 13.38M | - | 17.08M | 10.83M | 5.44M | 5.21M | -41.84M | 8.19M | 1.50M | -3.49M | -2.02M | -12.61M | -456.28M | -10.90M | 36.34M | -15.92M | -17.00M |
| Diluted EPS | 0.25 | 0.25 | 0.24 | 0.22 | 0.26 | 0.20 | 0.22 | 0.20 | 0.24 | 0.23 | 0.33 | 0.32 | 0.33 | 0.29 | 0.31 | 0.25 | 0.30 | 0.14 | 0.15 | 0.11 | 0.15 | 0.15 | 0.15 | 0.12 | 0.15 | 0.16 | 0.10 | 0.05 | 0.05 | -0.19 | 0.04 | 0.01 | -0.02 | -0.01 | -0.06 | -2.10 | -0.05 | 0.17 | -0.07 | -0.08 |
| R&D Expense | - | 2.57M | 2.62M | 2.45M | - | 2.68M | 2.77M | 2.64M | - | 3.10M | 2.97M | 2.84M | - | 2.82M | 3.17M | 3.25M | - | 3.69M | 3.78M | 3.82M | - | 3.88M | 4.06M | 4.24M | - | 4.33M | 4.33M | 4.56M | 4.88M | 6.85M | 7.26M | 6.72M | 5.76M | 4.85M | 5.20M | 5.11M | 4.50M | 5.12M | 4.56M | 3.80M |
Profit & Loss (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.51M | 172.68M | 184.05M | 207.53M | 247.41M | 283.07M | 321.27M | 358.28M | 397.93M | 414.19M | 418.17M | 468.46M | 527.16M | 822.45M | 924.22M | 894.66M |
| Gross Profit | 72.97M | 87.79M | 92.42M | 109.49M | 122.60M | 139.69M | 153.06M | 168.92M | 186.27M | 191.92M | 196.28M | 215.06M | 243.01M | 405.95M | 463.90M | 421.38M |
| Operating Income | 26.88M | 35.84M | 33.74M | 40.71M | 43.39M | 53.12M | 56.39M | 64.94M | 70.19M | 68.09M | 67.52M | 74.17M | 58.62M | 37.52M | 58.66M | -1.06B |
| Net Income | 17.52M | 22.84M | 22.51M | 27.19M | 28.16M | 33.53M | 36.56M | 43.79M | 63.15M | 60.18M | 59.48M | 60.88M | 48.31M | -22.87M | -9.42M | -1.09B |
| Diluted EPS | 0.76 | 0.96 | 0.62 | 0.75 | 0.76 | 0.90 | 0.72 | 0.86 | 1.21 | 0.57 | 0.56 | 0.57 | 0.45 | -0.12 | -0.04 | -5.03 |
| R&D Expense | 6.26M | 6.83M | 6.64M | 7.78M | 8.33M | 9.58M | 9.89M | 10.38M | 10.86M | 12.80M | 14.75M | 16.25M | 17.05M | 26.04M | 22.48M | 21.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | May 2009 | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 180.23M | 219.66M | 251.60M | 290.56M | 345.30M | 392.18M | 449.94M | 528.41M | 618.01M | 695.74M | 797.18M | 920.19M | 992.93M | 4.55B | 4.55B | 3.44B |
| Total Equity | 128.68M | 153.22M | 188.65M | 218.84M | 258.22M | 306.36M | 350.97M | 404.20M | 471.61M | 560.17M | 637.90M | 725.18M | 840.38M | 887.37M | 3.13B | 3.14B | 2.07B |
| Cash & Equivalents | 13.84M | 22.81M | 35.84M | 49.05M | 50.03M | 40.67M | 66.06M | 55.26M | 77.57M | 83.07M | 41.69M | 66.27M | 75.60M | 44.47M | 163.24M | 170.61M | 129.00M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 885.44M | 888.39M | 874.81M |
| Total Liabilities | - | - | 30.68M | 32.55M | 32.27M | 39.00M | 41.22M | 45.78M | 56.65M | 57.83M | 57.84M | 72.00M | 79.81M | 105.56M | 1.42B | 1.40B | 1.37B |
| Current Liabilities | - | - | 17.80M | 19.98M | 17.72M | 24.97M | 25.46M | 28.60M | 36.00M | 38.69M | 38.25M | 48.49M | 53.60M | 77.84M | 145.47M | 154.32M | 174.01M |
Cash Flows (Annual)
Figures in USD.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 27.99M | 28.84M | 22.28M | 26.56M | 21.67M | 35.33M | 60.27M | 69.13M | 63.84M | 85.88M | 81.09M | 68.04M | 41.03M | 35.26M | 58.24M |
| Investing Cash Flow | -25.73M | -28.04M | -15.79M | -37.95M | -51.29M | -61.15M | -62.14M | -83.08M | -119.15M | -88.78M | -105.56M | -97.23M | 201.04M | -29.31M | -99.19M |
| Financing Cash Flow | 6.71M | 12.03M | 6.88M | 12.49M | 19.61M | 15.31M | 25.07M | 22.84M | 13.90M | 29.41M | 33.54M | 6.81M | -118.08M | 1.92M | -1.60M |
| Capital Expenditure | - | - | -1.50M | - | - | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | 20.78M | - | - | - | - | - | - | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | - | - | 3.13M | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | May 2010 | May 2011 | May 2012 | May 2013 | May 2014 | May 2015 | May 2016 | May 2017 | May 2018 | May 2019 | May 2020 | May 2021 | May 2022 | May 2023 | May 2024 | May 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 51.9% | 50.8% | 50.2% | 52.8% | 49.6% | 49.3% | 47.6% | 47.1% | 46.8% | 46.3% | 46.9% | 45.9% | 46.1% | 49.4% | 50.2% | 47.1% |
| Operating Margin % | 19.1% | 20.8% | 18.3% | 19.6% | 17.5% | 18.8% | 17.6% | 18.1% | 17.6% | 16.4% | 16.1% | 15.8% | 11.1% | 4.6% | 6.3% | -118.6% |
| Net Margin % | 12.5% | 13.2% | 12.2% | 13.1% | 11.4% | 11.8% | 11.4% | 12.2% | 15.9% | 14.5% | 14.2% | 13.0% | 9.2% | -2.8% | -1.0% | -122.1% |
| ROE % | 11.4% | 12.1% | 10.3% | 10.5% | 9.2% | 9.6% | 9.0% | 9.3% | 11.3% | 9.4% | 8.2% | 7.2% | 5.4% | -0.7% | -0.3% | -52.7% |
| ROCE % | - | 17.8% | 14.6% | 14.9% | 13.5% | 14.5% | 13.4% | 13.2% | 12.1% | 10.4% | 9.0% | 8.6% | 6.4% | 0.9% | 1.3% | -32.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.99% | 32.62M | $305.33M |
| 2 | Vanguard Portfolio Management LLC | 5.90% | 12.83M | $120.11M |
| 3 | T. Rowe Price Investment Management, Inc. | 4.67% | 10.16M | $95.12M |
| 4 | Vanguard Capital Management LLC | 4.39% | 9.57M | $89.53M |
| 5 | Dimensional Fund Advisors LP | 4.20% | 9.13M | $85.48M |
| 6 | ING Groep N.V. | 4.09% | 8.90M | $83.34M |
| 7 | State Street Corporation | 3.95% | 8.59M | $80.41M |
| 8 | Mackenzie Financial Corporation | 3.58% | 7.80M | $73.04M |
| 9 | Neuberger Berman Group, LLC | 3.56% | 7.75M | $72.56M |
| 10 | Hudson Bay Capital Management Lp | 2.99% | 6.50M | $60.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NEOG
Neogen (NASDAQ:NEOG) Stock Price Crosses Above 200 Day Moving Average - Time to Sell? - MarketBeat
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxQT3IxallubGUtNWFZTng4ZEczODFtOU1OWnp5aGVhTi1ER3FlNVo0R0JodEl4WDFsVUlyRTl0Vi1XNXdCcWVzVmdRWXVCVG4zaFhaOG8xc1pLeWljVHliLTNYTGJKbWo5TTNqU2tWQ2NDWkN2NTJUWXFFMmR0YVQtS0FwS09oS3FaWF9NUE…
Is it Worth Retaining NEOG Stock in Your Portfolio for Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPckVtb2tFVlBIS3lUYkZST21iV3lCSTdyZEZPYjR5dUN3QjNwblNIUlpSUkJzdERqZlJTTTkzbGhneVlNU3ZROWtfRG5EM3laUFVHeTRVeTA4YmpnRU1IWFlvMWcxWVBqbG1BYjBFUEpLQy1wbGpncURCanNUTHVwUWIwQzJ2bjFrSXE0R3…
Neogen (NEOG) Stock Could Be 26.4% Undervalued After Texas And Florida Product Expansion - simplywall.st
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOWkxhXzc1LXdRdk1QTTNVMzlybkxuVGltTzljS3dnNmVJX2VWYndqNjlfd3FGSGc4d1c4NVNXWUZpam1WNlNQQ1JCZXNTTWxmeFFkN2RUS090ZW1rOXJyd3o3VGZ0QnJpUlM5QlNYRlJ0aU5YQTlZYlBVNmVxaEFucHNhZ21YQTVTbU5mLW…
2 Small-Cap Stocks Worth Investigating and 1 We Avoid - StockStory
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQMXdLOHdYdE5JWHE1NHhsSlpCSWQyNVFKalNaQUhfczFSSkZGOUFpOTQ0LU95M1NhR1NfS0p0alJub1hYdU9oZ0hJUU5QelZlZkowNlJ5Skw1cGw5STVtcDM4NnNCTHQ3aTIwRm45U1hmTGdUalEyTlhFQWNzRFpKVWVxSTFxa3BRYW1OSk…
Liquidity Mapping Around (NEOG) Price Events - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxORlhEUGYxWDdOd1JRZDZBbjhpV1lodzlSUkZFM05Ba1A4a0lycG1PdU1hM1MwdVltd3dZMVN2TFp5eWN4WFFOc1BSTjBRMTc3YnUxVmRfckM4ekhwZGwwQWppZ2x5TWNfampkSVZQSUlTQXU4Ymd0dHptX0ZCX1J0Z3Y4YkZPRUo0aWtRNz…
Fund Update: New $55.4M $NEOG stock position opened by CIBC WORLD MARKET INC. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPVFdXdl9HbDE3MzhKclFWSVkxVF9wTkt0QXZ6Z0lsaG9xOXRta2VJbFI1bmh6aXdaZ3d5TFhRVDBVMVBYOG14TF9BeUtoSGk0cFluY1BSYVZDdGsycDg4Ri1fdEsxTGtncWx6eDdDZ29PdXpzU1c0Skp2ckR1eTFXdWltN1NNSGM5anFXMi…
NEOG — Frequently Asked Questions
What is the current share price of Neogen Corporation (NEOG)?
As of 2026-07-14 21:23 PDT, Neogen Corporation (NEOG) trades at $9.67 on NasdaqGS. Its 52-week range is $4.65 to $11.33.
What is the market capitalisation of NEOG?
Neogen Corporation (NEOG) has a market capitalisation of $2.10B on NasdaqGS.
What is the P/E ratio of NEOG?
NEOG trades at a trailing price-to-earnings (P/E) ratio of -3.45. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 0.94.
What is the return on equity (ROE) of NEOG?
NEOG has a return on equity (ROE) of -25.57%. Its return on capital employed (ROCE) is -32.45%.
Is NEOG a good stock to buy?
This page provides a data-driven analysis of Neogen Corporation (NEOG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.